Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice

Biochemical Pharmacology

Volumn 86, Issue 6, 2013, Pages 782-790

  Kim, Sun D ^a   Kim, Ha N ^a   Lee, Jong H ^a   Jin, Won J ^a   Hwang, Soon J ^a   Kim, Hong H ^a   Ha, Hyunil ^b   Lee, Zang Hee ^a  

^a Seoul National University   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Bone destruction; Calcium oscillation; NFATc1; RANKL; Trapidil

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR OF ACTIVATED T CELLS, CYTOPLASMIC 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROTEIN C FOS; PROTEIN KINASE B; PROTEIN KINASE PIM 1; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR; TRAPIDIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; BONE MASS; BONE MINERAL; CALCIUM SIGNALING; CONTROLLED STUDY; GENETIC TRANSDUCTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSIENT TRANSFECTION;

EID: 84885178634     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.07.015     Document Type: Article

References (46)

1. 2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunological Reviews 2009; 231: 241-56.
2. Arai F, Miyamoto T, OhnedaO, InadaT, Sudo T, BraselK, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. Journal of Experimental Medicine 1999; 190: 1741-54. (Pubitemid 30013841)
3. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76. (Pubitemid 28180851)
4. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. Journal of Biological Chemistry 2007; 282: 18245-53. (Pubitemid 47100255)
5. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental Cell 2002; 3: 889-901. (Pubitemid 35460788)
6. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004; 428: 758-63. (Pubitemid 38508286)
7. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 2008; 132: 794-806. (Pubitemid 351312796)
8. Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y, et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nature Medicine 2006; 12: 1410-6. (Pubitemid 44924500)
9. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010; 115: 766-74.
10. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. New England Journal of Medicine 2006; 354: 2006-13.
11. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111: 2538-47.
12. O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. Journal of Bone and Mineral Research 2007; 22: 1679-89. (Pubitemid 351235134)
13. Brownlow N, Russell AE, Saravanapavan H, Wiesmann M, Murray JM, Manley PW, et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2008; 22: 649-52. (Pubitemid 351386741)
14. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107: 4334-7. (Pubitemid 43801358)
15. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). Journal of Bone and Mineral Metabolism 2006; 24: 274-82. (Pubitemid 43992670)
16. Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. American Heart Journal 1992; 123: 1439-44.
17. Poon M, Cohen J, SiddiquiZ, Fallon JT, Taubman MB. Trapidil inhibits monocyte chemoattractant protein-1 and macrophage accumulation after balloon arterial injury in rabbits. Laboratory Investigation 1999; 79: 1369-75.
18. Deguchi J, Abe J, Makuuchi M, Takuwa Y. Inhibitory effects of trapidil on PDGF signaling in balloon-injured rat carotid artery. Life Sciences 1999; 65: 2791-9.
19. Mazurov AV, Menshikov M, Leytin VL, Tkachuk VA, Repin VS. Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil. FEBS Letters 1984; 172: 167-71. (Pubitemid 14098847)
20. Ohnishi H, Kosuzume H, Hayashi Y, Yamaguchi K, Suzuki Y, Itoh R. Effects of trapidil on thromboxane A2-induced aggregation of platelets, ischemic changes in heart and biosynthesis of thromboxane A2. Prostaglandins and Medicine 1981; 6: 269-81. (Pubitemid 11155261)
21. Zhou L, Ismaili J, Stordeur P, Thielemans K, Goldman M, Pradier O. Inhibition of the CD40 pathway of monocyte activation by triazolopyrimidine. Clinical Immunology 1999; 93: 232-8.
22. Sichelschmidt OJ, Hahnefeld C, Hohlfeld T, Herberg FW, Schror K. Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity. Cardiovascular Research 2003; 58: 602-10. (Pubitemid 36694446)
23. LotinunS, Sibonga JD, Turner RT. Triazolopyrimidine(trapidil),aplatelet- derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism. Endocrinology 2003; 144: 2000-7. (Pubitemid 36543340)
24. Turner RT, Iwaniec UT, Marley K, Sibonga JD. The roleofmast cellsinparathyroid bone disease. Journal of Bone and Mineral Research 2010; 25: 1637-49.
25. Lee JH, Kim HN, Yang D, Jung K, Kim HM, Kim HH, et al. Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. Journal of Biological Chemistry 2009; 284: 13725-34.
26. Kim HN, Lee JH, Jin WJ, Ko S, Jung K, Ha H, et al. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice. European Journal of Pharmacology 2012; 691: 69-76.
27. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nature Reviews Immunology 2007; 7: 292-304. (Pubitemid 46480961)
28. Kim HJ, Lee Y, Chang EJ, Kim HM, Hong SP, Lee ZH, et al. Suppression of osteoclastogenesis by N, N-dimethyl-D-erythro-sphingosine: a sphingosine kinase inhibition-independent action. Molecular Pharmacology 2007; 72: 418-28. (Pubitemid 47124122)
29. HuangH, Chang EJ, RyuJ, Lee ZH, Lee Y, Kim HH. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochemical and Biophysical Research Communications 2006; 351: 99-105. (Pubitemid 44635412)
30. Ikeda Y, Kaneko A, Yamamoto M, Ishige A, Sasaki H. Possible involvement of suppression of Th2 differentiation in the anti-allergic effect of Sho-seiryu-to in mice. Japanese Journal of Pharmacology 2002; 90: 328-36. (Pubitemid 36096888)
31. Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY, et al. Akt induces osteoclast differentiation through regulating the GSK3beta/NFATc1 signaling cascade. Journal of Immunology 2012; 188: 163-9.
32. Kim K, Kim JH, Youn BU, Jin HM, Kim N. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-kappaB activation and NFATc1 induction. Journal of Immunology 2010; 185: 7460-6.
33. Somuncu S, Cakmak M, Erdogan S, Caglayan O, Caglayan F, Akman H, et al. Protective effects of trapidil in lung after abdominal aorta induced ischemiareperfusion injury: an experimental study. Pediatric Surgery International 2005; 21: 983-8. (Pubitemid 41720309)
34. Avlan D, Taskinlar H, Tamer L, Camdeviren H, Ozturhan H, Ozturk C, et al. Protective effect of trapidil against oxidative organ damage in burn injury. Burns 2005; 31: 859-65. (Pubitemid 41398109)
35. Buyukafsar K, Yazar A, Dusmez D, Ozturk H, Polat G, Levent A. Effect of trapidil, an antiplatelet and vasodilator agentongentamicin-induced nephrotoxicity in rats. Pharmacological Research 2001; 44: 321-8. (Pubitemid 32977925)
36. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-41. (Pubitemid 40248339)
37. O'Sullivan S, Lin JM, Watson M, Callon K, Tong PC, Naot D, et al. The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone 2011; 49: 281-9.
38. Liu FC, Graybiel AM. Spatiotemporal dynamics of CREB phosphorylation: transient versus sustained phosphorylation in the developing striatum. Neuron 1996; 17: 1133-44. (Pubitemid 27021099)
39. 2+ oscillation-independent NFATc1 activation during osteoclasto-genesis. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 8643-8. (Pubitemid 351987733)
40. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276-87.
41. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnoverbybisphosphonates onmicrodamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524-31. (Pubitemid 32416465)
42. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. Journal of Bone and Mineral Research 2000; 15: 613-20. (Pubitemid 30174014)
43. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorpho-metric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. Journal of Clinical Investigation 1997; 100: 1475-80. (Pubitemid 27425772)
44. Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 31: 620-5. (Pubitemid 35449706)
45. Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, Kasperk C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. Journal of Bone and Mineral Research 2011; 26: 503-11.
46. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine 2004; 350: 459-68. (Pubitemid 38133766)